Compugen (CGEN) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Compugen Ltd. has announced promising data on the anti-tumor activity and safety of its triple combination therapy involving COM701, COM902, and pembrolizumab in patients with platinum-resistant ovarian cancer. These findings, presented at the Society for Immunotherapy of Cancer Annual Meeting, highlight the potential of COM701 as a differentiated immune checkpoint inhibitor, offering hope for improved treatment options. The company’s confidence in advancing COM701 is bolstered by consistent data from multiple studies, suggesting a unique mechanism of action that may enhance progression-free survival in ovarian cancer patients.
For further insights into CGEN stock, check out TipRanks’ Stock Analysis page.
